Verastem, Inc.
Clinical trials sponsored by Verastem, Inc., explained in plain language.
Verastem, Inc.
VSTM
NASDAQ
A biopharmaceutical company developing drugs to treat cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill targets Hard-to-Treat lung cancer mutation Results expected Jun 2027 (estimated) May already have reported ↗
- New pill targets stubborn colorectal cancer mutation Results expected Jun 2027 (estimated) May already have reported ↗
- New pill targets tough pancreatic cancer mutation Results expected Jun 2027 (estimated) May already have reported ↗
- Can a Two-Drug combo keep fighting a rare ovarian cancer? Results expected Aug 2027 (estimated)